Passage Bio, Inc. Common Stock
PASGStock
$4.91−34.61%52W
Market Cap$15.90M
P/E—
Div yield—
Beta1.44
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-84.62%
Price vs S&P 500 (4W)-18.88%
VGM Score17.99
Market Capitalization$15.90M
Earnings Surprise History
Q1 26-2.16est. -2.85
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.31
3.83
3.91
3.89
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PASGPassage Bio, Inc. Common Stock | — | — | F | $4.91 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Passage Bio develops genetic medicines for rare monogenic CNS disorders, including GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The company targets the underlying causes of these neurodegenerative conditions to address significant unmet medical needs.